Last reviewed · How we verify

NCT03765944

Bioequivalence Study of NPC-12 (Sirolimus) Granules and Tablets

Completed Phase 1 Last updated 25 February 2019
What this trial tests

Phase 1 trial testing sirolimus in Bioequivalence Study in 10 participants. Completed in 29 December 2018.

Timeline
5 December 2018
Primary endpoint
29 December 2018
29 December 2018

Quick facts

Lead sponsorNobelpharma
PhasePhase 1
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingnone
Primary purposeother
Enrollment10
Start date5 December 2018
Primary completion29 December 2018
Estimated completion29 December 2018
Sites1 location across Japan

Drugs / interventions tested

Conditions studied

Sponsor

Nobelpharma — full company profile →

Who can join

Adults 20 to 39, any sex, with Bioequivalence Study. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the bioequivalece of NPC-12 granules in compare with NPC-12T tablets in Japanese healthy Adults

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of sirolimus

Trials testing the same drug.

Other Nobelpharma trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03765944.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing